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effect of the administration of exogenous NO in the set-
ting of ischemia-reperfusion after solid organ transplan-
tation.5-8
Tetrahydrobiopterin is an essential cofactor of all NO
synthases (NOSs; Fig 1). Activation of NOSs under
suboptimal concentrations of tetrahydrobiopterin leads
to increased formation of oxygen radicals,9 which
E ndothelial dysfunction is the central pathophysio-logic mechanism of ischemia-reperfusion injury.
Nitric oxide (NO) plays a key role in a number of basic
endothelium-dependent mechanisms such as vasodila-
tion,1 modulation of neutrophil adhesion,2 platelet
aggregation,3 and maintenance of endothelial barrier
properties.4 Recent studies demonstrate the protective
Objective: Exogenous nitric oxide reduces ischemia-reperfusion injury
after solid organ transplantation. Tetrahydrobiopterin, an essential
cofactor for nitric oxide synthases, may restore impaired endothelium-
dependent nitric oxide synthesis. We evaluated whether tetrahydro-
biopterin administration to the recipient attenuates lung reperfusion
injury after transplantation in swine. Methods: Unilateral left lung trans-
plantation was performed in 15 weight-matched pigs (24-31 kg). Donor
lungs were flushed with 1.5 L cold (1°C) low-potassium-dextran solution
and preserved for 20 hours. Group I animals served as controls. Group
II and III animals were treated with a bolus of tetrahydrobiopterin (20
mg/kg). In addition, in group III a continuous infusion of tetrahydro-
biopterin (10 mg/kg per hour over 5 hours) was given. One hour after
reperfusion, the recipient right lung was occluded. Cyclic guanosine
monophosphate levels were measured in the pulmonary venous and cen-
tral venous blood. Extravascular lung water index, hemodynamic vari-
ables, lipid peroxidation, and neutrophil migration to the allograft were
assessed. Results: In group III a significant reduction of extravascular
lung water was noted in comparison with the controls (P = .0047). Lipid
peroxidation in lung allograft tissue was significantly reduced in group
II (P = .0021) and group III (P = .0077) in comparison with group I.
Pulmonary venous levels of cyclic guanosine monophosphate increased
up to 23 ± 1 pmol/mL at 5 hours in group II and up to 40 ± 1 pmol/mL
in group III (group I, 4.1 ± 0.5 pmol/mL [I vs III]; P < .001), whereas
central venous levels of cyclic guanosine monophosphate were
unchanged in all groups. Conclusion: Tetrahydrobiopterin administra-
tion during lung allograft reperfusion may reduce posttransplantation
lung edema and oxygen-derived free radical injury in the graft. This
effect is mediated by local enhancement of the nitric oxide/cyclic guano-
sine monophosphate pathway. (J Thorac Cardiovasc Surg 1999;118:
726-32)
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mediate oxidative vascular injury.10 Furthermore, it has
been shown that exogenous tetrahydrobiopterin
restores impaired endothelium-derived NO synthesis in
acute endothelial dysfunction.11
In a model of unilateral lung transplantation in swine,
we investigated whether exogenous tetrahydrobiopterin
enhances the NO/cyclic guanosine monophosphate
(cGMP) pathway. In addition, we evaluated whether this
treatment reduces posttransplantation lung ischemia-
reperfusion injury after prolonged preservation.
Material and methods
Animals and operative procedure. All animals received
humane care in compliance with the European Convention on
Animal Care. The protocol was approved by the local animals
study committee. Fifteen weight-matched pairs of outbred
pigs (24-31 kg) served as donors and recipients. Harvest and
left lung transplantations were performed as previously
reported.12 Preservation time was 20 hours at 1°C. One hour
after reperfusion, the right contralateral lung was excluded
from perfusion and ventilation.
Study groups. Animals were randomized into 3 groups.
Group I (n = 5) served as controls, and no tetrahydrobiopterin
was administered. In group II (n = 5), the recipient animals
were treated with tetrahydrobiopterin, 20 mg/kg, given as a
30-minute bolus infusion started 15 minutes before reperfu-
sion. In group III (n = 5), in addition to the bolus, tetrahydro-
biopterin was continuously infused at a dose of 10 mg/kg per
hour during the entire 5-hour observation time.
Administration of tetrahydrobiopterin. Buffered solu-
tions of (6R)-5,6,7,8-tetrahydro-L-biopterin-dihydrochloride
(BH4; Dr B. Schircks Laboratories, Jona, Switzerland), 10
and 20 mg/kg body weight, respectively, were prepared
directly before use as previously described.13 After dilution
with 0.9% NaCl to a total volume of 50 mL, the solution was
passed through a 0.2-m m pyrogen-free filter (Schleicher &
Schuell, Feldbach, Switzerland). The light-protected solution
was infused by an IVAC perfusor (IVAC Corporation, San
Diego, Calif) at a constant flow of 99.9 mL/h for bolus infu-
sion and 50 mL/h for continuous infusion, respectively.
Assessment. One hour after reperfusion of the transplanted
lung, the right contralateral pulmonary arteries and the right
main bronchus were ligated to assess allograft function only.
During the assessment period, anesthesia was maintained
with halothane (Fluothane) 1.5%. Systemic arterial, pul-
monary arterial, central venous, and left atrial pressure were
recorded continuously. In addition, pulmonary venous and
central venous blood was drawn for analysis of cGMP at the
beginning of the assessment and hourly thereafter.
At the end of the assessment period, 5 hours after reperfu-
sion, the animals were killed. Upper lobe allograft samples
were taken for tissue myeloperoxidase and thiobarbituric acid
reactive substance assay.
Extravascular lung water. Extravascular lung water
(EVLW) as direct assessment of the reperfusion edema was
measured as previously described.12 Thoracic intravascular
and extravascular fluid volumes are determined on the basis
of the measurement of the mean transit times for thermal and
dye indicators and of the decay time volumes calculated from
the indicator-dilution curves as described previously.14 The
lung water computer (System Cold Z-021; Pulsion, Munich,
Germany) detects the mean transit time for the thermal indi-
cator and for the dye indicator and calculates total thermal
volume (ITTV), intrathoracic blood volume (ITBV), and
extravascular thermal volume (ETV).15 The extravascular
thermal volume (ETV) is calculated as follows: ETV = ITTV
– ITBV. All measurements are made in triplicate. The mean
value is used for analysis and expressed as EVLW index
(EVLWI) in milliliters per kilogram of body weight.
Neutrophil migration. Donor and recipient lung samples
were frozen immediately and stored at –80°C until assay.
Quantitative myeloperoxidase activity as the measurement
for neutrophil migration into the allograft was determined by
routine methods as previously described.16 Enzyme activity is
expressed as change in optical density (at 460 nm) per mil-
ligram of tissue protein per minute (D OD/mg/min).
Lipid peroxidation. Donor and recipient lung samples
were frozen immediately and stored at –80°C until assay.
Thiobarbituric acid reactive substance levels were measured
according to the method of Ohkawa and associates17 in 10%
wet weight per volume homogenate. Myeloperoxidase lev-
els were determined by reference to a standard curve of
1,1,3,3-tetramethoxypropane (Sigma Chemicals, Buchs,
Switzerland), and the results were expressed as picomoles
of malondialdehyde per gram of wet lung.
Measurement of plasma cGMP levels. Concentrations of
cGMP were determined in pulmonary venous blood drawn
from the left atrium and in peripheral venous blood drawn
from the right ventricle of the recipient. Plasma was pre-
pared and frozen at –80°C until analysis by EIA (Biotrak
cGMP assay; Amersham International plc, Amersham,
United Kingdom) according to the manufacturer’s instruc-
tions. The detection limit of the assay used was 46 fmol/
well.
Hemodynamic variables. Systemic arterial, pulmonary
arterial, central venous, and left atrial pressure were recorded
Fig 1. BH4 acts as essential coenzyme of NOSs to form NO
and citrulline from L-arginine. NO stimulates the soluble
guanylate cyclase to form cGMP, the second messenger of NO.
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continuously with a hemodynamic monitor system (Hellige,
Freiburg, Germany). Measurement of cardiac output is part of
the lung water assessment (System Cold Z-021; Pulsion), the
pulmonary vascular resistance was calculated in CGS units
according to Poiseuille’s law.
Statistical analysis. All values are given as the mean ±
standard error of the mean. Analysis for repeated measures
was performed by analysis of variance (StatView 4.5; Abacus
Concepts, Inc, Berkeley, Calif).
Results
Characteristics of experimental groups. No statis-
tical differences between groups were noted in donor
Fig 2. EVLW in the pulmonary allograft increased in the first 120 minutes after reperfusion followed by a slight
decrease in the control group. The development of posttransplantation lung edema was significantly lower in the
BH4-treated animals (mean ± SEM).
Fig 3. Leukocyte adhesion and lipid peroxidation. Polymorphonuclear migration measured as myeloperoxidase
activity shows an increase after transplantation, but remarkably less in groups II and III . Thiobarbituric acid reac-
tive substance (TBARS) levels in the allograft as the measurement for lipid peroxidation 5 hours after reperfusion
were significantly reduced by treatment with tetrahydrobiopterin (mean ± SEM).
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weight (27.1 ± 2.8 kg in group I vs 29.6 ± 3.7 kg in
group II; P = .57, and 28.5 ± 6.0 in group III; P = .65),
recipient weight (27.6 ± 5.1 kg in group I vs 27.6 ± 2.1
kg in group II; P = .75, and 26.8 ± 5.2 kg in group III;
P = .81), total preservation time (1218 ± 37 minutes in
group I vs 1197 ± 22 minutes in group II; P = .25, and
1222 ± 22 minutes in group III; P = .81), and warm
ischemic time (90 ± 6 minutes in group I vs 89 ± 3
minutes in group II; P = .94, and 88 ± 5 minutes in
group III; P = .65) Values are given as the mean ± stan-
dard error of the mean.
Reperfusion edema. As shown in Fig 2, EVLWI in
the allograft was significantly lower in animals treated
continuously with BH4 (overall difference group III vs
group I; P = .020). This effect was most marked 2 hours
after reperfusion (10.1 ± 0.6 mL/kg in group I vs 7.0 ±
0.5 mL/kg in group III; P = .0047). In group II, a ten-
dency to reduced edema formation (EVLWI) in com-
parison to the controls was noted (overall difference
group II vs group I; P = .14).
Neutrophil migration. Allograft myeloperoxidase
activity tended to be lower after administration of BH4.
Even though data were suggestive for an inhibition of
neutrophil adhesion, the differences were not statisti-
cally significant (1.37 ± 0.22 D OD/mg/min in group I
vs 1.13 ± 0.15 D OD/mg/min in group II; P = .39, and
0.94 ± 0.08 D OD/mg/min in group III; P = .17).
Myeloperoxidase activity in normal unflushed lung tis-
sue was 0.42 ± 0.09 D OD/mg/min (Fig 3).
Lipid peroxidation. A significant change of malon-
Fig 4. cGMP levels in pulmonary (A) and central venous blood (B) of lung allograft recipients (mean ± SEM).
The highest levels of cGMP were noted when the animals were treated with BH4 continuously.
A
B
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dialdehyde concentration was shown in lung allograft
tissue in group II, 65.7 ± 7.9 pmol/g (P = .0021) and
group III, 68.2 ± 11.3 pmol/g (P = .0077) versus group
I, 120.8 ± 0.7 pmol/g (malondialdehyde concentration
in normal lung tissue 41.3 ± 4.2 pmol/g; Fig 3).
Changes of cGMP levels. On BH4 administration,
pulmonary venous cGMP levels increased during 5
hours up to 23 ± 1 pmol/mL in group II and up to 40 ±
1 pmol/mL in group III at the end of the assessment
compared with untreated animals (group I 4.13 ± 0.49
pmol/mL; P < .001 group I vs III; Fig 4, A). In all
groups central venous cGMP was unchanged during the
5-hour observation period (at the end of the assessment
in group I 7.1 ± 0.1 pmol/mL, in group II 7.2 ± 0.4
pmol/mL, and in group III 7.8 ± 2.5 pmol/mL; Fig 4, B).
Hemodynamic parameters. No significant differ-
ences were noted in hemodynamic variables either dur-
ing the 5-hour assessment period or at the end of the
assessment: cardiac output (3.1 ± 0.4 L/min in group I
vs 4.2 ± 0.4 L/min in group II and 3.3 ± 0.2 L/min in
group III; P = .50), pulmonary arterial pressure (32 ± 3
mm Hg in group I vs 36 ± 4 mm Hg in group II and 32
± 1 mm Hg in group III; P = .60), and pulmonary vas-
cular resistance (580 ± 85 dynes · sec–1 · cm-5 in group
I vs 557 ± 152 dynes · sec–1 · cm-5 in group II and 575
± 48 dynes · sec–1 · cm-5 in group III; P = .69; Fig 5).
Discussion
In the present study we demonstrate that BH4 treat-
ment during lung allograft reperfusion enhances pul-
monary venous cGMP levels and reduces post-trans-
plant lung edema in a large animal model. This reduc-
tion, however, was statistically significant only when
BH4 was administered continuously over the entire
observation period. cGMP levels increased up to 10
times over control levels in the pulmonary venous
blood of the graft. However, an improvement in pul-
monary hemodynamics was not observed. This is in
accordance with previous reports that noted that only
infusion of high doses of BH4 in the brachial artery in
human beings led to a marked local vasodilation.18 For
substitution of NO-dependent vasodilation in patients
with impaired endothelial function as the result of
hypercholesteremia, however, relatively low doses of
BH4 were sufficient.19 In addition, other effects were
noted that indicate a reduction in reperfusion injury in
our experiment. These include a reduction of oxy-
gen/derived free radical–mediated injury and an at least
suggestive reduction in neutrophil migration to the
allograft. Even though we did not directly show that the
cGMP levels were enhanced through the NO pathway,
it is most probable that BH4 increases NO production
by NOS because the known biologic role of BH4 is to
act only as coenzyme of NOS and for the synthesis of
neurotransmitters and amino acids.
Gas exchange, in this model, is not a parameter that
can be used to assess the injury. If the ischemic time of
the graft would be expanded to induce a reduction of
gas exchange after reperfusion, the animal would die
within 1 or 2 hours after reperfusion, and no repro-
Fig 5. Pulmonary vascular resistance (PVR). Pulmonary vascular resistance increased at the time of exclusion of
the right native lung (60 min). BH4 treatment did not reduce this increase of pulmonary vascular resistance (mean
± SEM). 
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ducible data could be assessed. Moreover, the lung
water computer used in this highly reproducible model
allows for the assessment of hemodynamic variables
and the dynamic changes of the lung edema.
Impaired endothelium-dependent NO synthesis after
ischemia-reperfusion has been observed by a number
of investigators, and different strategies have been pro-
posed to substitute this endothelial dysfunction. In the
lung for example, administration of L-arginine20 or NO
donors21 and NO inhalation7,22 have been evaluated in
experimental and/or clinical settings. From the theoret-
ic standpoint, L-arginine substitution does not increase
NO synthesis, because intracellular L-arginine (0.8-2
mmol/L) concentration is much higher than the con-
centration at which the reaction velocity is half maxi-
mal (2.9 mmol/L).23 Intravascular administration of
NO donors affect the systemic circulation and NO
inhalation, although having the advantage to be selec-
tive for the target organ is cumbersome for routine and
prophylactic administration. Moreover, BH4 has some
specific properties to qualify as the limiting step for
NO synthesis in dysfunctional endothelium after
ischemia and reperfusion. It increases the affinity of
NOS to L-arginine24; it stabilizes NOSs,25 and it
inhibits the negative feedback of NO on NOSs.26 In the
absence of BH4, NOSs no longer produce NO but cat-
alyze reactions leading to oxygen-derived free radical
production.27 In addition, BH4 has a very low toxicity13
and can be administered even in high doses simply by
the intravenous route.
Tiefenbacher and associates11 previously demonstrat-
ed in vitro, in isolated pig coronary arterioles, that
exogenous administration of sepiapterin or the synthet-
ic derivative 6-methyl-tetrahydropterin restores the
response to endothelium-dependent vasodilators after
ischemia and reperfusion and that limited availability of
BH4 contributes to impaired endothelial vasodilation.
In conclusion, our study shows for the first time the
effect of the NOS cofactor BH4 on post-transplantation
ischemia-reperfusion injury in a large animal model.
We could demonstrate that the administration of exoge-
nous BH4 is a promising new therapeutic approach to
substitute impaired NO/cGMP pathway after ischemia
and reperfusion, resulting in reduced post-transplant
edema in this complex and clinically relevant model of
lung allograft reperfusion injury.
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Discussion
Dr Paolo Macchiarini (Hannover, Germany). Was the 20-
hour period chosen to induce a forced pulmonary edema or
because you wanted to prolong or extend the ischemic time?
The amount of pulmonary edema seems not that impressive
to me. For instance, in the control group you had 10.1 mL/kg
and in the treated group 8.4 or 7 mL/kg. Therefore what is
your clinical impression concerning really this difference and
the treatment? I think that the weakest point of this study is
that you did not clamp the right pulmonary artery, and there-
fore the respiratory support was dependent on both lungs. 
Dr Schmid. Last question first: We did occlude the right
pulmonary artery 1 hour after reperfusion. 
Dr Macchiarini. Okay. Sorry. Thank you very much. 
Dr Schmid. Maybe you are also working with the pig
model. It is a very difficult model, because if you induce too
much damage to the lung, the pigs die within a short time of
right heart failure. This is our standard model: 20 hours from
preservation time, prostaglandin E1 (alprostadil) and low-
potassium dextran solution to achieve reproducible results.
Everything we can add to this high standard is for us quite
impressive. We are now performing experiments with a
preservation time of 30 hours using BH4 and cGMP. We think
this supports the importance of the NO pathway during lung
allograft reperfusion. 
Dr Mark F. Ferguson (Chicago, Ill). In terms of group III,
when you added the 8-Br-cGMP to the flush solution, why
did you eliminate the prostaglandin E1? 
Dr Schmid. We wanted to do a direct comparison between
prostaglandin E1 and 8-Br-cGMP. We did not want to demon-
strate that it is an additive effect, but we wanted to compare the
standard with prostaglandin E1 to cGMP in the flush solution. 
Dr Ferguson. Then do you think that there is an additive
effect possible? 
Dr Schmid. I guess so, because there are 2 different path-
ways. To evaluate an additive effect, we would need another
group. I mean, you can do groups infinitely. 
Dr Ferguson. Yes, that is right. The analog, 8-Br-cGMP,
has the effects that are identical to cGMP? 
Dr Schmid. Yes. A number of studies showed the mecha-
nism in small animal models, the uptake in the endothelium
and in the smooth muscle cells. 
Dr Ferguson. Then tell me what the disadvantage would
be of infusing that instead of using it in the flush. 
Dr Schmid. We do not have the explanation yet. It is more
effective if you give it in the flush solution. For intravenous
administration to the recipient, we had to detect the dose first.
If you give too much cGMP to the recipient, you have prob-
lems with systemic hypotension, which we can avoid if we
give it in the flush solution. 
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